Indeed, a first-in-human clinical trial of Dabrafenib, Trametinib, and Pembrolizumab (NCT02130466) in 15 patients with BRAF-mutated metastatic melanoma found that the combination of BRAF and MEK inhibitors with PD-1 blocking therapy induced an objective responses in 11 patients (73%) (Ribas et al., 2019). The gene discussed is PDCD1; the disease is metastatic melanoma.